Compositions and methods for treating rotator cuff injuries

Abstract

The present invention provides compositions and methods for attaching tendon to bone. The present invention provides compositions and methods for treating rotator cuff injuries. In one embodiment, a method for treating rotator cuff injuries comprises providing a composition comprising PDGF disposed in a biocompatible matrix and applying the composition to at least one site of tendon reattachment on the humeral head.

1 - 18 . (canceled) 
     
     
         19 . An implant consisting essentially of a scaffolding material saturated with a solution of platelet-derived growth factor (PDGF) in a buffer, wherein
 the scaffolding material consists essentially of i) a porous collagen patch or pad, or ii) a porous collagen patch or pad and a biocompatible binder; and   the solution has a PDGF concentration ranging from about 0.1 to 1.0 about mg/mL.   
     
     
         20 . The implant of  claim 19 , wherein the scaffolding material consists essentially of the collagen. 
     
     
         21 . The implant of  claim 19 , wherein the collagen is a fibrous collagen. 
     
     
         22 . The implant of  claim 21 , wherein the fibrous collagen is selected from a type I collagen, a type II collagen, a type III collagen, and any combination thereof. 
     
     
         23 . The implant of  claim 22 , wherein the collagen is a type I collagen. 
     
     
         24 . The implant of  claim 23 , wherein the collagen is type I bovine collagen. 
     
     
         25 . The composition of  claim 19 , wherein the collagen has a density ranging from about 0.75 g/cm 3  to about 1.5 g/cm 3 . 
     
     
         26 . The composition of  claim 19 , wherein the collagen has a wet tear strength ranging from about 0.75 pounds to about 5 pounds. 
     
     
         27 . The composition of  claim 19 , wherein the collagen is capable of absorbing water in an amount ranging from about 1× to 15× the mass of the collagen. 
     
     
         28 . The composition of  claim 19 , wherein the solution has a PDGF-BB concentration ranging from about 0.2 to about 0.4 mg/mL. 
     
     
         29 . The composition of  claim 19 , wherein the solution has a PDGF-BB concentration of about 0.3 mg/mL. 
     
     
         30 . The composition of  claim 19 , wherein the scaffolding material comprises pores having a size distribution between about 1 microns to about 1,000 microns. 
     
     
         31 . The composition of  claim 19 , wherein the PDGF-BB solution is disposed within the pores of the scaffolding material. 
     
     
         32 . The composition of  claim 19 , wherein the biocompatible binder is selected from the group consisting of alginic acid, arabic gum, guar gum, xantham gum, gelatin, chitin, chitosan, chitosan acetate, chitosan lactate, chondroitin sulfate, N,O-carboxymethyl chitosan, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, sodium dextran sulfate, fibrin glue, lecithin, phosphatidylcholine derivatives, glycerol, hyaluronic acid, sodium hyaluronate, methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, a glucosamine, a proteoglycan, a starch, lactic acid, pluronic acid, sodium glycerophosphate, glycogen, a keratin, silk, and derivatives and mixtures thereof. 
     
     
         33 . The composition of  claim 19 , wherein the PDGF-BB is recombinant human (rh) PDGF-BB. 
     
     
         34 . The composition of  claim 19 , wherein the PDGF-BB comprises a combination of intact rhPDGF-B (1-109) and fragments thereof. 
     
     
         35 . The composition of  claim 19 , wherein the PDGF-BB comprises at least 65% of intact rhPDGF-B (1-109). 
     
     
         36 . The composition of  claim 19 , wherein the buffer is sodium acetate.